Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction.
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2015
At a glance
- Drugs Dasatinib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 25 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Nov 2013 Planned number of patients changed from 45 to 42 as reported by ClinicalTrials.gov.